Skip to main content

Table 2 Association between clinical parameters and evolution in 120 patients with ITP

From: Impact of reticulin stain in clinical outcome of Immune Thrombocytopenic Purpura (ITP): a pathologist perspective

  Favorable outcome (n = 89) Unfavorable outcome
(n = 31)
p-value*
n % n %
Petechiae 60 67.4 20 64.5 0.466
Ecchymosis 71 79.8 23 74.2 0.339
Hematoma 19 21.3 6 19.4 0.518
Epistaxis 29 32.6 13 41.9 0.234
Purpura 21 23.6 6 19.4 0.415
Oral bleeding 45 50.6 16 51.6 0.543
Mucosal bleeding 41 46.1 13 41.9 0.427
Internal bleedinga 12 13.5 4 12.9 0.609
Anemia 18 20.2 6 19.4 0.572
Leukopenia 1 1.1 0 0.0 0.742
Lymphopenia 16 18.0 3 9.7 0.214
Thrombocytopenia 83 93.3 29 93.5 0.660
Infection 23 25.8 4 12.9 0.105
Splenomegaly 4 4.5 1 3.2 0.615
Non-hematological neoplasia 1 1.1 2 6.5 0.165
Chemotherapy/radiation therapy 0 0.0 1 3.2 0.258
Use of systemic medication 23 25.8 9 29.0 0.449
Systemic arterial hypertension 13 14.6 14 45.2 0.001
Diabetes mellitus 5 5.6 3 9.7 0.340
Dyslipidemia 5 5.6 6 19.4 0.033
Obesity 5 5.6 5 16.1 0.079
Smoking 13 11.2 3 9.7 0.555
Past autoimmune disease 4 4.5 1 3.2 0.615
Hypothyroidism 3 3.4 3 9.7 0.178
Viral hepatitis 3 3.4 6 19.4 0.009
H. pylori gastritis 6 6.7 2 6.4 0.622
  1. *Statistical tests used: Chi-square and Fisher exact. a Hemorrhages of the gastrointestinal tract, respiratory tract, or central nervous system